Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions

References

• Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363–79
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993–2000
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57:392–410
   PubMed Web of Science ®Google Scholar
• Banach M, Aronow WS, Serban M-C, et al. Lipids, blood pressure and kidney update 2015. Lipid Health Dis 2015;14:1
   PubMed Web of Science ®Google Scholar
• Colantonio LD, Bittner V, Reynolds K, et al. Association of serum lipids and coronary heart disease in contemporary observational studies. Circulation 2016;133:256–64
   PubMed Web of Science ®Google Scholar
• Kucera M, Oravec S, Hirnerova E, et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study. Angiology 2014;65:794–9
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314–24
   PubMed Web of Science ®Google Scholar
• Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904–10
   PubMed Web of Science ®Google Scholar
• Kamstrup PR. Lipoprotein(a) and ischemic heart disease-a causal association? A review. Atherosclerosis 2010;211:15–23
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844–53
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Targher G. Screening and therapeutic management of lipoprotein(a) excess: review of the epidemiological evidence, guidelines and recommendations. Clin Chim Acta 2011;412:797–801
   PubMed Web of Science ®Google Scholar
• Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metab Clin Exp 2013;62:479–91
   PubMed Web of Science ®Google Scholar
• Boffa MB, Koschinsky ML. Update on lipoprotein (a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep 2013;15:1–10
   Web of Science ®Google Scholar
• Scanu A, Nakajima K, Edelstein C. Apolipoprotein(a): structure and biology. Front Biosci 2001;6:D546–54
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Diffenderfer MR, Marcovina SM. Lipoprotein(a) metabolism. Curr Opin Lipidol 2014;25:189–93
   PubMed Web of Science ®Google Scholar
• Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol 1999;10:133–42
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331–9
   PubMed Web of Science ®Google Scholar
• Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009;203:371–6
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 2009;361:2518–28
   PubMed Web of Science ®Google Scholar
• Enkhmaa B, Anuurad E, Zhang W, et al. Lipoprotein(a): genotype–phenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord 2011;9:411–18
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 2012;60:722–9
   PubMed Web of Science ®Google Scholar
• Diffenderfer MR, Lamon-Fava S, Marcovina SM, et al. Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a). Metab Clin Exp 2016;65:381–90
   PubMed Web of Science ®Google Scholar
• Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E. Lipoprotein(a) – an independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl 2015;18:263–7
   PubMed Web of Science ®Google Scholar
• Bos S, Yayha R, van Lennep JER. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol 2014;25:452–60
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082–5
   PubMed Web of Science ®Google Scholar
• Collaboration ERF. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412
   PubMed Web of Science ®Google Scholar
• Genser B, Dias KC, Siekmeier R, et al. Lipoprotein (a) and risk of cardiovascular disease – a systematic review and meta analysis of prospective studies. Clin Lab 2011;57:143–56
   PubMed Web of Science ®Google Scholar
• Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44:2301–6
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Lipoprotein (a), cardiovascular disease, and contemporary management. Mayo Clin Proc 2013;88:1294–311
   PubMed Web of Science ®Google Scholar
• Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke a meta-analysis of observational studies. Stroke 2007;38:1959–66
   PubMed Web of Science ®Google Scholar
• Banach M, Bromfield S, Howard G, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol 2014;176:219–26
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Liu L, Mancia G, et al. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. A review of available rial evidence. J Hypertens 2014;32:1741–50
   PubMed Web of Science ®Google Scholar
• Denti L, Marchini L, Pasolini G, et al. Lipoprotein Lp(a) and cerebrovascular disease in the elderly: correlations with the severity of extracranial carotid atherosclerosis assessed by ultrasonography. Acta Biomed Ateneo Parmense 1995;66:175–83
   PubMedGoogle Scholar
• Kotani K, Shimohiro H, Adachi S, Sakane N. Relationship between lipoprotein(a), metabolic syndrome, and carotid atherosclerosis in older Japanese people. Gerontology 2008;54:361–4
   PubMed Web of Science ®Google Scholar
• Nave AH, Lange KS, Leonards CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 2015;242:496–503
   PubMed Web of Science ®Google Scholar
• Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis 2014;234:95–101
   PubMed Web of Science ®Google Scholar
• Langsted A, Varbo A, Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population. J Clin Endocrinol Metab 2015;100:2690–9
   PubMed Web of Science ®Google Scholar
• Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010;55:2160–7
   PubMed Web of Science ®Google Scholar
• Sofi F, Marcucci R, Abbate R, et al. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007;120:728–33
   PubMed Web of Science ®Google Scholar
• Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741–60
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail 2016;4:78–87
   PubMed Web of Science ®Google Scholar
• Narverud I, Retterstøl K, Iversen PO, et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis 2014;235:299–309
   PubMed Web of Science ®Google Scholar
• Baldassarre D, Tremoli E, Franceschini G, et al. Plasma lipoprotein (a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. Stroke 1996;27:1044–9
   PubMed Web of Science ®Google Scholar
• Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014;63:1982–9
   PubMed Web of Science ®Google Scholar
• Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015;36:2425–37
   PubMed Web of Science ®Google Scholar
• Myśliwiec M, Walczak M, Małecka-Tendera E, et al. Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish lipid expert forum. J Clin Lipid 2014;8:173–80
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Wierzbicki AS, Mikhailidis DP. Lipoprotein a: where are we now? Curr Opin Cardiol 2009;24:351–7
   PubMed Web of Science ®Google Scholar
• Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the sixth special issue. J Clin Apheresis 2013;28:145–284
   PubMed Web of Science ®Google Scholar
• Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013;128:2567–76
   PubMed Web of Science ®Google Scholar
• Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247–55
   PubMed Web of Science ®Google Scholar
• Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229–39
   PubMedGoogle Scholar
• Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2011;42:517–84
   PubMed Web of Science ®Google Scholar
• Kotani K, Sahebkar A, Serban MC, et al. Lipoprotein(a) levels in patients with abdominal aortic aneurysm: a systematic review and meta-analysis. Angiology 2016. [Epub ahead of print]. doi:10.1177/0003319716637792
   Google Scholar
• Ooi EM, Watts GF, Chan DC, et al. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2015;35:2686–93
   PubMed Web of Science ®Google Scholar
• Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes). J Am Coll Cardiol 2013;62:1575–9
   PubMed Web of Science ®Google Scholar
• Artemeva NV, Safarova MS, Ezhov MV, et al. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype. Atheroscler Suppl 2015;18:53–8
   PubMed Web of Science ®Google Scholar
• Lippi G, Targher G. Optimal therapy for reduction of lipoprotein(a). J Clin Pharm Ther 2012;37:1–3
   PubMed Web of Science ®Google Scholar
• Takagi H, Umemoto T. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int J Cardiol 2012;154:183–6
   PubMed Web of Science ®Google Scholar
• Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004;256:482–90
   PubMed Web of Science ®Google Scholar
• Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia N Engl J Med 1990;322:1494–9
   PubMed Web of Science ®Google Scholar
• Mullur R, Liu Y-Y, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev 2014;94:355–82
   PubMed Web of Science ®Google Scholar
• Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5:497–505
   PubMedGoogle Scholar
• Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381:40–6
   PubMed Web of Science ®Google Scholar
• Kotani K, Sahebkar A, Serban C, et al. Tibolone decreases lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis 2015;242:87–96
   PubMed Web of Science ®Google Scholar
• Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002;48:1454–9
   PubMed Web of Science ®Google Scholar
• Sheridan C. CETP inhibitors boost ‘good’ cholesterol to no avail. Nat Biotechnol 2016;34:5–6
   PubMed Web of Science ®Google Scholar
• Lewis CE. Defining the safety of anacetrapib, a CETP inhibitor, in patients at high risk for coronary heart disease: the DEFINE study. Curr Cardiovasc Risk Rep 2011;5:109–12
   PubMedGoogle Scholar
• Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015;386:1472–83
   PubMed Web of Science ®Google Scholar
• Romagnuolo R, Scipione CA, Boffa MB, et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015;290:11649–62
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Obradovic M, et al. PCSK9 inhibition – a novel mechanism to treat lipid disorders? Curr Pharm Des 2013;19:3869–77
   PubMed Web of Science ®Google Scholar
• Dragan S, Serban M-C, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther 2015;20:157–68
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Nasser SA. PCSK9 inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a). Cardiovasc Drugs Ther 2015;29:295–308
   PubMed Web of Science ®Google Scholar
• Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014;114:711–15
   PubMed Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014;63:1278–88
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163:40–51
   PubMed Web of Science ®Google Scholar
• Li C, Lin L, Zhang W, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015;4:e001937
   PubMed Web of Science ®Google Scholar
• Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010;5:e14328
   PubMed Web of Science ®Google Scholar
• Chennamsetty I, Claudel T, Kostner KM, et al. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 2012;32:1220–7
   PubMed Web of Science ®Google Scholar
• Rysz J, Gluba-Brzózka A, Mikhailidis DP, Banach M. Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. Expert Opin Investig Drugs 2015;24:603–10
   PubMed Web of Science ®Google Scholar
• Serban M-C, Sahebkar A, Mikhailidis DP, et al. Impact of L-carnitine on plasma lipoprotein (a) concentrations: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 2015;5:19188
   Web of Science ®Google Scholar
• Fukami K, Yamagishi S-i, Sakai K, et al. Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients. J Cardiovasc Pharmacol 2015;65:289–95
   PubMed Web of Science ®Google Scholar
• Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19:576–85
   PubMed Web of Science ®Google Scholar
• Wu W-K, Panyod S, Ho C-T, et al. Dietary allicin reduces transformation of L-carnitine to TMAO through impact on gut microbiota. J Func Foods 2015;15:408–17
   Web of Science ®Google Scholar
• Sahebkar A, Serban C, Ursoniu S, Banach M. Effect of garlic on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials. Nutrition 2016;32:33–40
   PubMed Web of Science ®Google Scholar
• Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med 2006;26:751–72
   PubMed Web of Science ®Google Scholar
• McConnell JP, Guadagno PA, Dayspring TD, et al. Lipoprotein(a) mass: a massively misunderstood metric. J Clin Lipidol 2014;8:550–3
   PubMed Web of Science ®Google Scholar
• Guadagno PA, Bellin EGS, Harris WS, et al. Validation of a lipoprotein (a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. Clin Chim Acta 2015;439:219–24
   PubMed Web of Science ®Google Scholar
• Lassman ME, McLaughlin TM, Zhou H, et al. Simultaneous quantitation and size characterization of apolipoprotein (a) by ultra‐performance liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2014;28:1101–6
   PubMed Web of Science ®Google Scholar
• Lanktree MB, Anand SS, Yusuf S, Hegele RA. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein (a) in South Asians, Chinese, and European Caucasians. Circulat: Cardiovasc Genet 2010;3:39–46
   PubMed Web of Science ®Google Scholar
• Li Z, Li G, Zhou Y, et al. Lack of association between lipoprotein (a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention. Lipid Health Dis 2013;12:127
   PubMed Web of Science ®Google Scholar
• Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol 2004;59:479–84
   PubMed Web of Science ®Google Scholar
• Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 2009;50:S376–81
   Google Scholar
• Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010;56:946–55
   PubMed Web of Science ®Google Scholar
• Yamada S, Morishita R, Nakamura S, et al. Development of antibody against epitope of lipoprotein(a) modified by oxidation: evaluation of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a). Circulation 2000;102:1639–44
   PubMed Web of Science ®Google Scholar
• Kotani K, Yamada S, Uurtuya S, et al. The association between blood glucose and oxidized lipoprotein(a) in healthy young women. Lipids Health Dis 2010;9:103
   PubMed Web of Science ®Google Scholar
• Kotani K, Yamada S, Yamada T, et al. The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: a comparison with native lipoprotein(a). Lipids Health Dis 2011;10:174
   PubMed Web of Science ®Google Scholar
• Kotani K, Yamada S, Yamada T, et al. Oxidized lipoprotein(a) and cardio-ankle vascular index (CAVI) in hypertensive subjects. Heart Vessels 2013;28:461–6
   PubMed Web of Science ®Google Scholar
• Kotani K, Sakane N. Carotid intima-media thickness in asymptomatic subjects with low lipoprotein(a) levels. J Clin Med Res 2012;4:130–4
   PubMedGoogle Scholar
• Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007;27:1788–95
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Kotani K, Kario K, et al. Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population. Thromb Res 2013;131:e54–8
   PubMed Web of Science ®Google Scholar
• Tanaka T, Okamura T. Blood cholesterol level and risk of stroke in community-based or worksite cohort studies: a review of Japanese cohort studies in the past 20 years. Keio J Med 2012;61:79–88
   PubMedGoogle Scholar
• Lippi G. Lipoprotein(a)-lowering therapies: a double edged sword? Atherosclerosis 2015;242:504–5
   PubMed Web of Science ®Google Scholar
• Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008;49:2230–9
   PubMed Web of Science ®Google Scholar
• Hsieh Wu J. Lipoprotein(a) in vascular disease, cancer and longevity. Chang Gung Med J 2011;34:555–64
   PubMedGoogle Scholar
• Trieu VN, Uckun FM. Apolipoprotein(a), a link between atherosclerosis and tumor angiogenesis. Biochem Biophys Res Commun 1999;257:714–8
   PubMed Web of Science ®Google Scholar
• Kim JS, Chang JH, Yu HK, et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 2003;278:29000–8
   PubMed Web of Science ®Google Scholar
• Panza F, D'Introno A, Capurso C, et al. Lipoproteins, vascular-related genetic factors, and human longevity. Rejuvenation Res 2007;10:441–58
   PubMed Web of Science ®Google Scholar
• Sawabe M, Tanaka N, Mieno MN, et al. Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study). PLoS One 2012;7:e31954
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003;49:1785–96
   PubMed Web of Science ®Google Scholar